Patent · US Active

Humanized anti-IL-1R3 antibodies

US12024564B2 · kind B2 · utility

1Cited by

13References

15Claims

0Family size

Assignee

SANOFI BIOTECHNOLOGY · FR

Inventors

Stephan Fischer · Weilheim, DE
Michael Brandt · Iffeldorf, DE
Linda Veronique Kazandjian · Munich, DE

Key dates

Filing date	Aug 24, 2021
Grant date	Jul 2, 2024
Priority date	—
Expiry date	Apr 8, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity.The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer.The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.